Tafluprost
- CAS No.
- 209860-87-7
- Chemical Name:
- Tafluprost
- Synonyms
- aflupros;TafL;MK2452;uprost;AFP-168;TAFLUPROST;Tafluprosttrade;MK2452|||AFP-168;Tafluprost USP/EP/BP;209860-87-7 Tafluprost
- CBNumber:
- CB3401660
- Molecular Formula:
- C25H34F2O5
- Molecular Weight:
- 452.53
- MOL File:
- 209860-87-7.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/11/15 19:19:13
| Boiling point | 552.9±50.0 °C(Predicted) |
|---|---|
| Density | 1.186 |
| storage temp. | 2-8°C |
| solubility | soluble in Chloroform, DMSO, Ethyl Acetate |
| form | Clear, colorless to slightly yellow oil |
| pka | 14.48±0.70(Predicted) |
| color | Colorless to light yellow |
| InChIKey | WSNODXPBBALQOF-VEJSHDCNSA-N |
| SMILES | C(OC(C)C)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COC1=CC=CC=C1 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS08,GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H372-H360-H319-H413-H370-H302 | |||||||||
| Precautionary statements | P264-P280-P305+P351+P338-P337+P313P-P260-P264-P270-P307+P311-P321-P405-P501-P264-P270-P301+P312-P330-P501-P260-P264-P270-P314-P501 | |||||||||
| NFPA 704 |
|
Tafluprost Chemical Properties,Uses,Production
Description
Glaucoma is second only to cataracts as a causative factor of blindness.
By 2010, it is estimated that approximately 60 million people worldwide
will be afflicted by glaucoma, so effective treatments should garner a large market.
PG analogs have been widely used for lowering IOP by increasing uveoscleral outflow through agonism of the prostanoid FP
receptor, and currently marketed versions include latanoprost, unoprostone isopropyl ester, bimatoprost, and travoprost.
Compared to the carboxylic acid of latanaprost
(Ki=4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greater
affinity for the prostanoid FP receptor (Ki=0.4 nM). The synthesis of
tafluprost begins with a Wittig condensation of the protected bicyclic
lactone carbaldehyde with a dimethyl phosphonate ketone derivative.
Compared to the carboxylic acid of latanaprost (Ki 4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greater affinity for the prostanoid FP receptor (Ki 0.4 nM). The synthesis of tafluprost begins with a Wittig condensation of the protected bicyclic lactone carbaldehyde with a dimethyl phosphonate ketone derivative. The bottom appendage is then completed by the fluorination of the ketone with morpholino-sulfur trifluoride. Hydrolysis of the benzoate ester protecting group liberates the hydroxy group, and reduction of the lactone is accomplished with aluminum hydride to generate the lactol. Condensation of this intermediate with the phosphonium salt of the acid side chain generates the free acid, or active ingredient, which is subsequently esterified with 2-iodopropane in the presence of DBU.
.
Uses
Tafluprost is a novel prostanoid used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula.
Uses
Tafluprost is a new potent PGF2_ analogue for the treatment of glaucoma and a potent and selective FP receptor agonist. It lowers intraocular pressure (IOP) primarily by increasing uveoscleral outflow. Tafluprost has been shown to have a potent IOP-lowering effect on elevated IOP caused by open-angle glaucoma, or by diseases known as ocular hypertension.
Definition
ChEBI: Tafluprost is a prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has a role as a prostaglandin receptor agonist. It is a prostaglandins Falpha, an organofluorine compound and an isopropyl ester. It is functionally related to a prostaglandin F2alpha.
Side effects
Common side effects of Tafluprost Eye Drops include: stinging or burning sensation, redness, itching, dryness and irritation of the eyes, darkening of the skin of the eyelids and changes in the length/thickness/number/colour of eyelashes. Patients with mixed colour irises may also experience darkening of the iris. Severe allergic reactions are rare and present with symptoms such as swelling of the face/eyes/lips/tongue, difficulty breathing, and an itchy rash around the eyes or over the body. Seek medical attention if any of these serious adverse reactions occur.
Mode of action
Tafluprost(209860-87-7) is a Prostaglandin Analog. The mechanism of action of tafluprost is as a Prostaglandin Receptor Agonist. It is believed that prostanoid FP-receptor agonists such as tafluprost reduce IOP by increasing the uveoscleral outflow of aqueous humor. There is some evidence that tafluprost may lower IOP by interaction with the EP3 receptor.
DB08819
Tafluprost Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Honour Lab Limited | +919845977466 | Telangana, India | 164 | 58 | Inquiry |
| Century Pharmaceuticals Ltd | +91-2652361581 +91-2652361581 | Gujarat, India | 53 | 58 | Inquiry |
| Aspen Biopharma Labs Pvt Ltd | +91-9248058660 +91-9248058662 | Telangana, India | 234 | 58 | Inquiry |
| Lucent Drugs Pvt Ltd | +91-8187000049 +91-9346111900 | Telangana, India | 11 | 58 | Inquiry |
| Vepan Pharmatech Pvt Ltd | +91-9908788828 +91-9966094448 | Telangana, India | 391 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6100 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6257 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6514 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
| Manus Aktteva Biopharma LLP | +91 79 26463394 | Gujarat, India | 275 | 58 | Inquiry |
209860-87-7(Tafluprost)Related Search:
1of4
chevron_right